Compare WBI & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBI | BHVN |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.1M | 1.1B |
| IPO Year | 2025 | 2017 |
| Metric | WBI | BHVN |
|---|---|---|
| Price | $23.01 | $11.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 15 |
| Target Price | $27.25 | ★ $30.36 |
| AVG Volume (30 Days) | 519.3K | ★ 2.9M |
| Earning Date | 03-16-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $733,296,000.00 | N/A |
| Revenue This Year | $21.70 | N/A |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.64 | $7.48 |
| 52 Week High | $27.12 | $44.28 |
| Indicator | WBI | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 45.86 |
| Support Level | $21.46 | $10.61 |
| Resistance Level | $22.52 | $12.90 |
| Average True Range (ATR) | 0.87 | 0.80 |
| MACD | 0.01 | -0.23 |
| Stochastic Oscillator | 38.46 | 17.66 |
WaterBridge Infrastructure LLC is integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates the largest produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling and handling produced water. It also operate two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment and handling of produced water is crucial to oil and natural gas production.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.